Multiple drugs

Multiple drugs Reactions 1680, p238 - 2 Dec 2017 sparing the neck and face. At the time of diagnosis, his steroid dose was 20 mg/day. Rituximab was discontinued. His steroid dose was tapered. At five months of follow-up, progression of disease was observed. Kaposi sarcoma and primary effusion lymphoma: Patient 5: A 44-year-old man, who had a history of retinal 5 case reports vasculitis, was receiving cyclophosphamide and steroids. He In a retrospective study consisting of 988 patients, five man was later started on rituximab infusion 375 mg/m at weeks 0, (aged 44-71 years) were described who developed Kaposi 1, 2 and 3. He was immunocompromised and had sarcoma (patient 1, 2, 3 and 4) and primary effusion lymphopenia. Four months after starting the rituximab lymphoma (patient 5) following treatment with rituximab and treatment, he was diagnosed with HHV-8 tumour based on steroids [specific drug not stated]. The HHV-8 tumour was also positive latency associated nuclear antigen1 immunostaining attributed to azathioprine and methotrexate (patient 1), and morphological analysis. He developed solid primary ciclosporin, mycophenolate mofetil and immune globulin effusion lymphoma. At the time of diagnosis, his steroid dose (patient 3), cyclophosphamide and azathioprine (patient 4) was 30 mg/day. Rituximab was discontinued. He was treated and cyclophosphamide (patient 5) [not all routes and dosages with chemotherapy. After 20 months, complete remission of stated; duration of treatments to reaction onsets not stated disease was observed. clearly]. Author comment: "In this study, we describe 5 HIV- Patient 1: A 52-year-old man, who had a history of negative male patients with HHV-8 tumors induced by RTX." necrotising myositis and Fitzpatrick skin phototype 4, was "However, other immunosuppressive therapies, such as receiving azathioprine, methotrexate and steroids. He was cyclophosphamide, methotrexate, and corticosteroids, are later started on rituximab infusion. Rituximab therapy prone to induce HHV-8 tumors in patients who are at risk." consisted of induction dose of 1gm on day 0 and day 15 and "Furthermore, all patients were immunocompromised by maintenance dose of 375 mg/m at month 5 and 1gm at previous treatments, including steroids, as indicated by the month 10. He was immunocompromised and had presence of lymphopenia." lymphopenia. Thirteen months after starting the rituximab treatment, he was diagnosed with HHV-8 tumour. Diagnosis Perier A, et al. De Novo Human Herpesvirus 8 Tumors Induced by Rituximab in was based on positive latency associated nuclear antigen1 Autoimmune or Inflammatory Systemic Diseases. Arthritis and Rheumatology 69: 2241-2246, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1002/ immunostaining and morphological analysis. He developed art.40217 - France 803284151 Kaposi sarcoma with skin lesions associated with classic papulonodular lesions sparing the neck, face and mucous membranes. Kaposi sarcoma was associated with lymph node enlargement and gut involvement. At the time of diagnosis, he was receiving steroid at a dose of 10 mg/day. Rituximab was discontinued. Dose of immunosuppressive agents was tapered and methotrexate was switched to mycophenolate mofetil. After 37 months, a partial remission of Kaposi sarcoma was observed. Patient 2: A 71-year-old man, who had a history of steroid- resistant nephropathy and homosexuality, was receiving steroids. He was started on rituximab infusion 375 mg/m at weeks 0, 1, 2 and 3. He had lymphopenia due to immunocompromisation. Three months after starting the rituximab treatment, he was diagnosed with HHV-8 tumour based on positive latency associated nuclear antigen1 immunostaining and morphological analysis. He developed Kaposi sarcoma with skin lesions associated with classic papulonodular lesions sparing the neck and face. At the time of diagnosis, his steroid dose was 35 mg/day. Rituximab was discontinued. He died 0.2 months after the diagnosis. Patient 3: A 56-year-old man, who had a history of heart transplant and Fitzpatrick skin type 6, was receiving ciclosporin, mycophenolate mofetil, IV immunoglobulin and steroids. He was later started on rituximab infusion 375 mg/m at weeks 0, 1, 2 and 3. He was immunocompromised and had lymphopenia. Four months after starting the rituximab treatment, he was diagnosed with HHV-8 tumour based on positive latency associated nuclear antigen1 immunostaining and morphological analysis. He developed Kaposi sarcoma with skin lesions and lymph node enlargement and gut, pulmonary and urogenital involvement. The skin lesions were primarily classic papulonodular lesions sparing the neck and face. At the time of diagnosis, his steroid dose was 20 mg/day. Rituximab was discontinued. He was treated with localised radiation therapy and chemotherapy. He died 20 months after the diagnosis. Patient 4: A 46-year-old man, who had a history of antisynthetase syndrome and Fitzprick skin phototype 6, was receiving cyclophosphamide, azathioprine and steroids. He was later started on rituximab infusion 1gm on days 0 and 15. He had lymphopenia due to immunocompromisation. Four months after starting the rituximab treatment, he was diagnosed with HHV-8 tumour based on positive latency associated nuclear antigen1 immunostaining and morphological analysis. He developed Kaposi sarcoma with skin lesions associated with classic papulonodular lesions 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Multiple drugs

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/multiple-drugs-8Xdj10jM1G
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39169-3
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p238 - 2 Dec 2017 sparing the neck and face. At the time of diagnosis, his steroid dose was 20 mg/day. Rituximab was discontinued. His steroid dose was tapered. At five months of follow-up, progression of disease was observed. Kaposi sarcoma and primary effusion lymphoma: Patient 5: A 44-year-old man, who had a history of retinal 5 case reports vasculitis, was receiving cyclophosphamide and steroids. He In a retrospective study consisting of 988 patients, five man was later started on rituximab infusion 375 mg/m at weeks 0, (aged 44-71 years) were described who developed Kaposi 1, 2 and 3. He was immunocompromised and had sarcoma (patient 1, 2, 3 and 4) and primary effusion lymphopenia. Four months after starting the rituximab lymphoma (patient 5) following treatment with rituximab and treatment, he was diagnosed with HHV-8 tumour based on steroids [specific drug not stated]. The HHV-8 tumour was also positive latency associated nuclear antigen1 immunostaining attributed to azathioprine and methotrexate (patient 1), and morphological analysis. He developed solid primary ciclosporin, mycophenolate mofetil and immune globulin effusion lymphoma. At the time of diagnosis, his steroid dose (patient 3), cyclophosphamide and azathioprine (patient 4) was 30 mg/day. Rituximab was discontinued. He was treated and cyclophosphamide (patient 5) [not all routes and dosages with chemotherapy. After 20 months, complete remission of stated; duration of treatments to reaction onsets not stated disease was observed. clearly]. Author comment: "In this study, we describe 5 HIV- Patient 1: A 52-year-old man, who had a history of negative male patients with HHV-8 tumors induced by RTX." necrotising myositis and Fitzpatrick skin phototype 4, was "However, other immunosuppressive therapies, such as receiving azathioprine, methotrexate and steroids. He was cyclophosphamide, methotrexate, and corticosteroids, are later started on rituximab infusion. Rituximab therapy prone to induce HHV-8 tumors in patients who are at risk." consisted of induction dose of 1gm on day 0 and day 15 and "Furthermore, all patients were immunocompromised by maintenance dose of 375 mg/m at month 5 and 1gm at previous treatments, including steroids, as indicated by the month 10. He was immunocompromised and had presence of lymphopenia." lymphopenia. Thirteen months after starting the rituximab treatment, he was diagnosed with HHV-8 tumour. Diagnosis Perier A, et al. De Novo Human Herpesvirus 8 Tumors Induced by Rituximab in was based on positive latency associated nuclear antigen1 Autoimmune or Inflammatory Systemic Diseases. Arthritis and Rheumatology 69: 2241-2246, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1002/ immunostaining and morphological analysis. He developed art.40217 - France 803284151 Kaposi sarcoma with skin lesions associated with classic papulonodular lesions sparing the neck, face and mucous membranes. Kaposi sarcoma was associated with lymph node enlargement and gut involvement. At the time of diagnosis, he was receiving steroid at a dose of 10 mg/day. Rituximab was discontinued. Dose of immunosuppressive agents was tapered and methotrexate was switched to mycophenolate mofetil. After 37 months, a partial remission of Kaposi sarcoma was observed. Patient 2: A 71-year-old man, who had a history of steroid- resistant nephropathy and homosexuality, was receiving steroids. He was started on rituximab infusion 375 mg/m at weeks 0, 1, 2 and 3. He had lymphopenia due to immunocompromisation. Three months after starting the rituximab treatment, he was diagnosed with HHV-8 tumour based on positive latency associated nuclear antigen1 immunostaining and morphological analysis. He developed Kaposi sarcoma with skin lesions associated with classic papulonodular lesions sparing the neck and face. At the time of diagnosis, his steroid dose was 35 mg/day. Rituximab was discontinued. He died 0.2 months after the diagnosis. Patient 3: A 56-year-old man, who had a history of heart transplant and Fitzpatrick skin type 6, was receiving ciclosporin, mycophenolate mofetil, IV immunoglobulin and steroids. He was later started on rituximab infusion 375 mg/m at weeks 0, 1, 2 and 3. He was immunocompromised and had lymphopenia. Four months after starting the rituximab treatment, he was diagnosed with HHV-8 tumour based on positive latency associated nuclear antigen1 immunostaining and morphological analysis. He developed Kaposi sarcoma with skin lesions and lymph node enlargement and gut, pulmonary and urogenital involvement. The skin lesions were primarily classic papulonodular lesions sparing the neck and face. At the time of diagnosis, his steroid dose was 20 mg/day. Rituximab was discontinued. He was treated with localised radiation therapy and chemotherapy. He died 20 months after the diagnosis. Patient 4: A 46-year-old man, who had a history of antisynthetase syndrome and Fitzprick skin phototype 6, was receiving cyclophosphamide, azathioprine and steroids. He was later started on rituximab infusion 1gm on days 0 and 15. He had lymphopenia due to immunocompromisation. Four months after starting the rituximab treatment, he was diagnosed with HHV-8 tumour based on positive latency associated nuclear antigen1 immunostaining and morphological analysis. He developed Kaposi sarcoma with skin lesions associated with classic papulonodular lesions 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off